The course, titled ‘Tissue Autofluorescence as An Aid in the Detection of Early Cancer and At-Risk Tissue,’ is offered through a partnership between BCCRC, an arm of the British Columbia Cancer Agency (BCCA), and Trimira.

Targeting dentists, periodontists, oral surgeons, primary-care physicians, and otolaryngologists, the electronic course is accredited by Health Science. The course instructs users in how to optimize Identafi 3000 ultra’s brilliant white, violet, and green-amber illumination.

Created exclusively for intraoral use, the cordless Identafi 3000 ultra is lightweight, portable, and ergonomically shaped. It incorporates a nickel-plated design that improves durability and delivers a smoother feel. The handheld is portable, and thus is readily moved from room to room and patient to patient.

Identafi 3000 ultra’s spectroscopic technology is effective in screening cancers in mucosal tissue. The same science works to help diagnose cervical, skin, gastrointestinal, and bladder cancers. Developed through the collaboration of three institutions BCCRC, The University of Texas, and Rice University Trimira’s multispectral technology represents a quantum leap in the visualization of mucosal abnormalities.

It also includes cancer or premalignant dysplasia Identafi 3000 ultra delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care.

Identafi 3000 ultra pinpoints biochemical and morphological changes in cells. The device’s violet wavelength capability was cited in the May 2009 issue of Cancer Prevention Research, the journal of the American Association for Cancer Research, as the best excitation wavelength to discriminate between neoplastic and non-neoplastic tissue areas.

Trimera is a privately held, Houston-based, medical diagnostic and imaging device company that has patented several cancer detection technologies, including the ‘multispectral’ technology which minimizes false positives in oral tissue and reveals abnormalities missed by the naked eye.